# US 2020/0206200 A1 · Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206200 A1
- Document ID: US20200206200A1
- Status: Published application
- Kind: A1
- Application number: 16/815,575
- Filed: 2020-03-11
- Published: 2020-07-02
- Earliest claimed: 2015-07-09
- Assignees: Santen Pharmaceutical Co., Ltd.
- Applicants: Santen Pharmaceutical Co., Ltd.
- Inventors: Tomoko KIRIHARA; Atsushi SHIMAZAKI; Najam A. SHARIF
- Web page: https://patentgrep.com/patent/US20200206200A1

## CPC

- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The object of the present invention is to find a new application of isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof. Isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminometh yl}pyridin-2-ylamino) acetate or a salt thereof is useful as a therapeutic agent for a disease involving a greatly elevated intraocular pressure.

## Claims

### Claim 1

A method for preventing and/or treating a disease involving a greatly elevated intraocular pressure, comprising administering isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminometh yl}pyridin-2-ylamino) acetate or a salt thereof to patients with said disease which has to be prevented and/or treated, wherein the greatly elevated intraocular pressure is a disease with an intraocular pressure in a range from 25 to 100 mmHg.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the disease involving a greatly elevated intraocular pressure is acute primary angle closure, primary angle closure glaucoma, secondary angle closure glaucoma, or acute intraocular pressure elevation.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the administration amount of the isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminometh yl}pyridin-2-ylamino)acetate or the salt thereof is 0.001 to 0.03% (w/v).

### Claim 4 (depends on 1)

The method according to claim 1, wherein any other prophylactic and/or therapeutic agent for glaucoma or ocular hypertension than isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminometh yl}pyridin-2-ylamino)acetate or a salt thereof is not administered.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the administration is instillation.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the disease involving a greatly elevated intraocular pressure is the acute intraocular pressure elevation which is caused by inflammation.
